18.08.2017
The National Cancer Institute estimates that approximately 5,970 people in the United States will be diagnosed with ALL this year and approximately 1,440 will die from the disease. "Based on the results seen in the INO-VATE ALL trial, Besponsa improved multiple efficacy measures, including rates of hematologic remission, MRD-negativity and stem cell transplantation", Hagop Kantarjian, lead investigator for the INO-VATE ALL study, said in an August 17 statement from Pfizer .